Titre
Treatment of Obesity with Thyroid hormones in Europe. Data from the THESIS* Collaboration.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Galofré, J.C.
Auteure/Auteur
Díez, J.J.
Auteure/Auteur
Attanasio, R.
Auteure/Auteur
Nagy, E.V.
Auteure/Auteur
Negro, R.
Auteure/Auteur
Papini, E.
Auteure/Auteur
Perros, P.
Auteure/Auteur
Žarković, M.
Auteure/Auteur
Akarsu, E.
Auteure/Auteur
Alevizaki, M.
Auteure/Auteur
Ayvaz, G.
Auteure/Auteur
Bednarczuk, T.
Auteure/Auteur
Beleslin, B.N.
Auteure/Auteur
Berta, E.
Auteure/Auteur
Bodor, M.
Auteure/Auteur
Borissova, A.M.
Auteure/Auteur
Boyanov, M.
Auteure/Auteur
Buffet, C.
Auteure/Auteur
Burlacu, M.C.
Auteure/Auteur
Dobnig, H.
Auteure/Auteur
Fadeyev, V.
Auteure/Auteur
Field, BCT
Auteure/Auteur
Fliers, E.
Auteure/Auteur
Führer, D.
Auteure/Auteur
Hakala, T.
Auteure/Auteur
Jiskra, J.
Auteure/Auteur
Kopp, P.
Auteure/Auteur
Krebs, M.
Auteure/Auteur
Kršek, M.
Auteure/Auteur
Kužma, M.
Auteure/Auteur
Lantz, M.
Auteure/Auteur
Lazúrová, I.
Auteure/Auteur
Leenhardt, L.
Auteure/Auteur
Luchytskiy, V.
Auteure/Auteur
Puga, F.M.
Auteure/Auteur
McGowan, A.
Auteure/Auteur
Metso, S.
Auteure/Auteur
Moran, C.
Auteure/Auteur
Morgunova, T.
Auteure/Auteur
Niculescu, D.A.
Auteure/Auteur
Perić, B.
Auteure/Auteur
Planck, T.
Auteure/Auteur
Poiana, C.
Auteure/Auteur
Robenshtok, E.
Auteure/Auteur
Rosselet, P.O.
Auteure/Auteur
Ruchala, M.
Auteure/Auteur
Riis, K.R.
Auteure/Auteur
Shepelkevich, A.
Auteure/Auteur
Tronko, M.
Auteure/Auteur
Unuane, D.
Auteure/Auteur
Vardarli, I.
Auteure/Auteur
Visser, W.E.
Auteure/Auteur
Vryonidou, M.
Auteure/Auteur
Younes, Y.R.
Auteure/Auteur
Hegedüs, L.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
1720-8386
Statut éditorial
Publié
Date de publication
2025-01
Volume
48
Numéro
1
Première page
201
Dernière page/numéro d’article
212
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
The use of thyroid hormones (TH) to treat obesity is unsupported by evidence as reflected in international guidelines. We explored views about this practice, and associations with respondent characteristics among European thyroid specialists.
Specialists from 28 countries were invited to a survey via professional organisations. The relevant question was whether "Thyroid hormones may be indicated in biochemically euthyroid patients with obesity resistant to lifestyle interventions".
Of 17,232 invitations 5695 responses were received (33% valid response rate; 65% women; 90% endocrinologists). Of these, 290 (5.1%) stated that TH may be indicated as treatment for obesity in euthyroid patients. This view was commoner among non-endocrinologists (8.7% vs. 4.7%, p < 0.01), private practice (6.5% vs. 4.5%, p < 0.01), and varied geographically (Eastern Europe, 7.3%; Southern Europe, 4.8%; Western Europe, 2.7%; and Northern Europe, 2.5%). Respondents from Northern and Western Europe were less likely to use TH than those from Eastern Europe (p < 0.01). Gross national income (GNI) correlated inversely with this view (OR 0.97, CI: 0.96-0.97; p < 0.001). Having national guidelines on hypothyroidism correlated negatively with treating obesity with TH (OR 0.71, CI: 0.55-0.91).
Despite the lack of evidence, and contrary to guidelines' recommendations, about 5% of respondents stated that TH may be indicated as a treatment for obesity in euthyroid patients resistant to life-style interventions. This opinion was associated with (i) respondent characteristics: being non-endocrinologist, working in private practice, treating a small number of hypothyroid patients annually and (ii) national characteristics: prevalence of obesity, Eastern Europe, low GNI and lack of national hypothyroidism guidelines.
Specialists from 28 countries were invited to a survey via professional organisations. The relevant question was whether "Thyroid hormones may be indicated in biochemically euthyroid patients with obesity resistant to lifestyle interventions".
Of 17,232 invitations 5695 responses were received (33% valid response rate; 65% women; 90% endocrinologists). Of these, 290 (5.1%) stated that TH may be indicated as treatment for obesity in euthyroid patients. This view was commoner among non-endocrinologists (8.7% vs. 4.7%, p < 0.01), private practice (6.5% vs. 4.5%, p < 0.01), and varied geographically (Eastern Europe, 7.3%; Southern Europe, 4.8%; Western Europe, 2.7%; and Northern Europe, 2.5%). Respondents from Northern and Western Europe were less likely to use TH than those from Eastern Europe (p < 0.01). Gross national income (GNI) correlated inversely with this view (OR 0.97, CI: 0.96-0.97; p < 0.001). Having national guidelines on hypothyroidism correlated negatively with treating obesity with TH (OR 0.71, CI: 0.55-0.91).
Despite the lack of evidence, and contrary to guidelines' recommendations, about 5% of respondents stated that TH may be indicated as a treatment for obesity in euthyroid patients resistant to life-style interventions. This opinion was associated with (i) respondent characteristics: being non-endocrinologist, working in private practice, treating a small number of hypothyroid patients annually and (ii) national characteristics: prevalence of obesity, Eastern Europe, low GNI and lack of national hypothyroidism guidelines.
Sujets
PID Serval
serval:BIB_B7ABFF006068
PMID
Open Access
Oui
Date de création
2024-06-21T09:05:52.121Z
Date de création dans IRIS
2025-05-20T22:12:51Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
38878126_BIB_B7ABFF006068.pdf
Version du manuscrit
published
Licence
https://creativecommons.org/licenses/by/4.0
Taille
1.15 MB
Format
Adobe PDF
PID Serval
serval:BIB_B7ABFF006068.P001
URN
urn:nbn:ch:serval-BIB_B7ABFF0060683
Somme de contrôle
(MD5):6ac2a6060ea3d5906815f8b377dd6866